GlassScriptPhysician profile
Tiffanie Thy DO
NPI 1194251710
$1,275.42
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $134 · 2021: $599 · 2022: $543.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $282.19 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $194.11 | 2020-2021 | |
| Genzyme Corporation | $126.46 | 2022 | |
| Seagen INC. | $125.76 | 2022 | |
| Celgene Corporation | $112.13 | 2022 | |
| Karyopharm Therapeutics INC. | $109.80 | 2021 | |
| Glaxosmithkline, LLC. | $102.28 | 2021 | |
| Pfizer INC. | $82.90 | 2020-2021 | |
| Incyte Corporation | $51.48 | 2020-2022 | |
| Exelixis INC. | $39.19 | 2020-2021 | |
| Stemline Therapeutics INC. | $26.21 | 2022 | |
| Merck Sharp & Dohme LLC | $22.91 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffanie DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.